Insider Transactions in Q1 2025 at Bristol Myers Squibb CO (BMY)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,610
-5.89%
|
$227,430
$63.11 P/Share
|
|
Mar 10
2025
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
3,121
-4.24%
|
-
|
|
Mar 10
2025
|
Robert M Plenge EVP, Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,255
+13.71%
|
-
|
|
Mar 10
2025
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
7,173
-19.17%
|
$451,899
$63.11 P/Share
|
|
Mar 10
2025
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Other acquisition or disposition
|
Direct |
6,403
-11.85%
|
-
|
|
Mar 10
2025
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Exercise of conversion of derivative security
|
Direct |
20,423
+29.7%
|
-
|
|
Mar 10
2025
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,711
-14.39%
|
$422,793
$63.11 P/Share
|
|
Mar 10
2025
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
SELL
Other acquisition or disposition
|
Direct |
7,333
-11.05%
|
-
|
|
Mar 10
2025
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
23,150
+27.72%
|
-
|
|
Mar 10
2025
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
16,056
-5.03%
|
$1,011,528
$63.11 P/Share
|
|
Mar 10
2025
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Other acquisition or disposition
|
Direct |
12,711
-3.41%
|
-
|
|
Mar 10
2025
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
44,098
+10.67%
|
-
|
|
Mar 10
2025
|
Phil M Holzer SVP and Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,820
-3.11%
|
$114,660
$63.11 P/Share
|
|
Mar 10
2025
|
Phil M Holzer SVP and Controller |
SELL
Other acquisition or disposition
|
Direct |
2,113
-3.12%
|
-
|
|
Mar 10
2025
|
Phil M Holzer SVP and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
7,140
+9.5%
|
-
|
|
Mar 10
2025
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,248
-13.64%
|
$141,624
$63.11 P/Share
|
|
Mar 10
2025
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Other acquisition or disposition
|
Direct |
2,213
-8.83%
|
-
|
|
Mar 10
2025
|
Lynelle Hoch President, Cell Therapy Org. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,446
+26.02%
|
-
|
|
Mar 10
2025
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
17,710
-1.21%
|
$1,115,730
$63.11 P/Share
|
|
Mar 10
2025
|
Sandra Leung EVP, General Counsel |
SELL
Other acquisition or disposition
|
Direct |
14,097
-0.92%
|
-
|
|
Mar 10
2025
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
48,718
+3.07%
|
-
|
|
Mar 10
2025
|
Ahn Amanda Poole EVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,273
-10.93%
|
$143,199
$63.11 P/Share
|
|
Mar 10
2025
|
Ahn Amanda Poole EVP, Chief People Officer |
SELL
Other acquisition or disposition
|
Direct |
2,119
-7.44%
|
-
|
|
Mar 10
2025
|
Ahn Amanda Poole EVP, Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,164
+22.27%
|
-
|
|
Mar 10
2025
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,065
-12.51%
|
$382,095
$63.11 P/Share
|
|
Mar 10
2025
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
4,830
-7.11%
|
-
|
|
Mar 10
2025
|
Adam Lenkowsky EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,684
+21.56%
|
-
|
|
Mar 10
2025
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,797
-4.3%
|
$1,373,211
$63.11 P/Share
|
|
Mar 10
2025
|
Christopher S. Boerner Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
17,424
-3.0%
|
-
|
|
Mar 10
2025
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,034
+9.35%
|
-
|
|
Mar 10
2025
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,935
-2.35%
|
$1,318,905
$63.11 P/Share
|
|
Mar 10
2025
|
David V Elkins EVP, Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
20,171
-2.07%
|
-
|
|
Mar 10
2025
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
69,517
+6.59%
|
-
|
|
Mar 10
2025
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
1,940
-6.06%
|
$122,220
$63.11 P/Share
|
|
Mar 10
2025
|
Cari Gallman EVP, Corporate Affairs |
SELL
Other acquisition or disposition
|
Direct |
2,345
-5.65%
|
-
|
|
Mar 10
2025
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
7,588
+15.66%
|
-
|
|
Mar 01
2025
|
Benjamin Hickey President, RayzeBio Org. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,630
-15.64%
|
$96,170
$59.62 P/Share
|
|
Mar 01
2025
|
Benjamin Hickey President, RayzeBio Org. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,286
+23.98%
|
-
|
|
Feb 20
2025
|
Christopher S. Boerner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+1.88%
|
$110,000
$55.05 P/Share
|
|
Feb 14
2025
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Open market or private purchase
|
Direct |
1,823
+2.77%
|
$98,442
$54.84 P/Share
|
|
Feb 01
2025
|
Benjamin Hickey President, RayzeBio Org. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,725
-34.31%
|
$216,050
$58.95 P/Share
|
|
Feb 01
2025
|
Benjamin Hickey President, RayzeBio Org. |
BUY
Exercise of conversion of derivative security
|
Direct |
10,078
+48.14%
|
-
|
|
Feb 01
2025
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
833
-10.64%
|
$48,314
$58.95 P/Share
|
|
Feb 01
2025
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,543
+24.52%
|
-
|